Quantcast

Unioversity College London develops anti-phospholipid syndrome treatment with Abzena’s technology, gets £3.5m grant from the Medical Research Council

A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.

Read more